EMA tags aTyr's Resolaris an Orphan Drug for LGMD; shares ahead 10% premarket

|About: aTyr Pharma (LIFE)|By:, SA News Editor

Thinly traded nano cap aTyr Pharma (NASDAQ:LIFE) is up 10% premarket on average volume in response to its announcement that the European Medicines Agency (EMA) has designated Resolaris an Orphan Drug for the treatment of limb girdle muscular dystrophy (LGMD).

Among the benefits of Orphan Drug status in the EU is a 10-year period of market exclusivity for the indication, if approved.

The U.S. FDA tagged Resolaris an Orphan Drug for LGMD a few days ago.

Previously: Resolaris an Orphan Drug for limb girdle muscular dystrophy; aTyr up 19% (Feb. 28)

Subscribe for full text news in your inbox